The Mitochondrial Peptide Revolution

Most peptides in the Atlas are synthetic — designed in labs, manufactured, and administered. But MOTS-c, SS-31 (elamipretide), and Humanin belong to a different category entirely. These are mitochondrial-derived peptides (MDPs) — short peptides encoded within the mitochondrial genome that your body already produces.

This distinction matters because it changes the therapeutic framing from "adding something foreign" to "restoring something that declines with age." Mitochondrial function deteriorates predictably as we get older, and MDP levels decline in parallel. The research question isn't whether these peptides do something useful — it's whether supplementing them can meaningfully slow or reverse age-related decline.

MOTS-c has generated excitement as a potential exercise mimetic — it activates AMPK, the same energy-sensing pathway triggered by physical activity. In animal models, MOTS-c improves insulin sensitivity, reduces obesity, and enhances exercise capacity even in aged mice.

The mechanistic story is compelling: MOTS-c translocates to the nucleus under metabolic stress and directly regulates gene expression related to glucose metabolism and antioxidant defense. It's not just a signaling molecule — it's a transcription factor that your mitochondria deploy when energy demands increase.

Human data is still early but growing. Observational studies show MOTS-c levels correlate inversely with age and metabolic disease. Interventional trials are now beginning, and the question is whether exogenous MOTS-c can replicate in humans what it does in mice.

SS-31 is the most clinically advanced of the mitochondrial peptides, having completed multiple Phase II and Phase III trials. Unlike MOTS-c and Humanin, SS-31 is synthetic — designed to target cardiolipin in the inner mitochondrial membrane and restore electron transport chain function.

The clinical data is mixed but instructive. In Barth syndrome (a rare mitochondrial cardiomyopathy), elamipretide showed functional improvement in a Phase II/III trial (TAZPOWER), with 168-week open-label extension data confirming sustained benefit. This led to FDA approval of elamipretide for Barth syndrome in 2025 — making it the first approved mitochondria-targeted peptide therapy. In the MMPOWER-3 trial for primary mitochondrial myopathy, overall results were mixed, though post hoc analysis identified genotype-specific responders. In age-related macular degeneration, results were less clear. A single-dose randomized trial in older adults showed elamipretide improved mitochondrial ATP production in skeletal muscle.

What SS-31 teaches us is that mitochondrial-targeted therapy works — but the challenge is finding the right patient populations. Mitochondrial dysfunction is ubiquitous in aging, but the degree to which any single organ benefits from targeted therapy varies.

Humanin was the first mitochondrial-derived peptide discovered (2001), and its story begins with Alzheimer's disease. It was identified in a screen for factors that protect neurons from amyloid-beta toxicity. A landmark 2003 study in Nature demonstrated that Humanin suppresses apoptosis by directly interfering with Bax activation — providing a clear mechanistic basis for its cytoprotective effects.

Since then, Humanin has shown cytoprotective effects across an extraordinary range of models: cardiovascular disease, diabetes, cancer, and neurodegeneration. It appears to function as a broad-spectrum cellular stress response signal. Animal studies have shown Humanin regulates both lifespan and healthspan, with long-lived species like naked mole rats exhibiting higher Humanin levels.

The paradox of Humanin is that its effects are so broad that it's been difficult to identify a specific therapeutic niche. In human observational data, higher circulating Humanin levels are associated with better cognitive function in the elderly and lower cardiovascular risk. A 2023 systematic review cataloged Humanin's pathophysiological roles across aging-related conditions. But translating this into a therapeutic strategy remains a challenge — do you supplement Humanin directly, or find ways to boost endogenous production?

The mitochondrial peptide field represents a paradigm shift in how we think about aging interventions. Rather than targeting downstream consequences (wrinkles, muscle loss, cognitive decline), these peptides target the upstream driver — mitochondrial dysfunction itself.

The evidence is strongest at the mechanistic level: we understand what these peptides do, how they work, and why they decline with age. The gap is in large-scale human outcomes data. SS-31 has now crossed the regulatory threshold with FDA approval for Barth syndrome, but even its broader results highlight how difficult it is to translate mitochondrial science into reliable clinical benefits across diverse populations.

Beyond these three peptides, the MDP family continues to grow — small humanin-like peptides (SHLPs) and other mitochondrial open reading frame-encoded peptides are being characterized, each with distinct signaling properties. A 2020 review in the American Journal of Physiology mapped the emerging roles of MDPs in energy metabolism, suggesting this field has much further to expand.

For the peptide-curious, this is a space to watch closely. The science is real, the rationale is sound, and the first regulatory approval has arrived — but we're still in the early chapters of proving these therapies work broadly in practice.